Loading
A phase 1/2 trial of Fulvestrant and HRS-8080 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients is a phase 1/2 interventional study registered as NCT06555068 by Jiangsu HengRui Medicine Co., Ltd., with 528 participants planned, started 2024-08-12 and due to reach its primary completion in 2027-12. Interventions recorded: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole, HRS-6209 in Combination with HRS-8080, HRS-6209 in Combination with HRS-9813 and Letrozole and HRS-6209 in Combination with HRS-9813 and HRS-8080.
Shares HRS-8080, Fulvestrant, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.